



In the claims:

1. (Original) A compound of Formula I:



wherein:

Y is selected from:



----- represents an optional double bond;

X is C, N, S(O)_m or O;

G is H₂ or O;

R^a is independently selected from:

- 1) H,
- 2) C₁-C₆ alkyl,
- 3) Halogen,
- 4) Aryl,
- 5) Heterocycle,
- 6) C₃-C₁₀ cycloalkyl, or
- 7) OR⁴;

said alkyl, aryl, heterocycle and cycloalkyl is optionally substituted with at least one substituent selected from R⁷;

R¹ is independently selected from:

- 1) H,
- 2) (CR^a₂)_nR⁶,
- 3) (CR^a₂)_nC(O)R⁴,
- 4) C(O)N(R⁴)₂,
- 5) (CR^a₂)_nOR⁴,
- 6) (CR^a₂)_nN(R⁴)₂,
- 7) S(O)_mR⁶,
- 8) S(O)_mR⁶OR⁴,
- 9) C(O)N(R⁴)(CR^a₂)_nR⁶,
- 10) C(O)N(R⁴)(CR^a₂)_nOR⁴,
- 11) C(O)R⁶(CR^a₂)_nR⁶,
- 12) C(O)N(R⁴)(CR^a₂)_nS(O)_m(CR^a₂)_nR⁶,
- 13) C(O)N(R⁴)(CR^a₂)_nC(O)R⁶,
- 14) C(O)N(R⁴)(CR^a₂)_nN(R⁴)₂,
- 15) Halogen,

- 16) $N(R^4)S(O)_mR^6$,
- 17) $(CR^{a2})_nC(O)OR^4$, and
- 18) $R^6C(O)OR$;

R^2 is:

- 1) H,
- 2) unsubstituted or substituted C_1 - C_{10} alkyl,
- 3) $N(R^4)_2$,
- 4) OR^4 ,
- 5) unsubstituted or substituted aryl, and
- 6) unsubstituted or substituted C_3 - C_{10} cycloalkyl;

R^4 is independently selected from:

- 1) H,
- 2) C_1 - C_6 alkyl,
- 3) C_3 - C_{10} cycloalkyl,
- 4) Aryl,
- 5) Heterocycle,
- 6) CF_3 ,
- 7) C_2 - C_6 alkenyl, and
- 8) C_2 - C_6 alkynyl;

said alkyl, cycloalkyl, aryl, heterocycle, alkenyl and alkynyl is optionally substituted with at least one substituent selected from R^7 ;

R^5 is independently selected from:

- 1) H,
- 2) Halogen,
- 3) NO_2 ,
- 4) CN,
- 5) $CR^4=C(R^4)_2$,

- 6) $C \equiv CR^4$,
- 7) $(CR^{a2})_nOR^4$,
- 8) $(CR^{a2})_nN(R^4)_2$,
- 9) $C(O)R^4$,
- 10) $C(O)OR^4$,
- 11) $(CR^{a2})_nR^4$,
- 12) $S(O)_mR^6$,
- 13) $S(O)_mN(R^4)_2$,
- 14) $OS(O)_mR^6$,
- 15) $N(R^4)C(O)R^4$,
- 16) $N(R^4)S(O)_mR^6$,
- 17) $(CR^{a2})_nN(R^4)R^6$,
- 18) $(CR^{a2})_nN(R^4)R^6OR^4$,
- 19) $(CR^{a2})_nN(R^4)(CR^{a2})_nC(O)N(R^4)_2$,
- 20) $N(R^4)(CR^{a2})_nR^6$,
- 21) $N(R^4)(CR^{a2})_nN(R^4)_2$,
- 22) $(CR^{a2})_nC(O)N(R^4)_2$,
- 23) $O(CR^{a2})_nC(O)OR^4$, and
- 24) $O(CR^{a2})_nC(O)N(R^4)_2$;

R^6 is independently selected from:

- 1) C_1 - C_6 alkyl,
- 2) Aryl,
- 3) Heterocycle, and
- 4) C_3 - C_{10} cycloalkyl;

said alkyl, aryl, heterocycle and cycloalkyl is optionally substituted with at least one substituent of R^7 ;

R^7 is independently selected from:

- 1) Unsubstituted or substituted C_1 - C_6 alkyl,
- 2) Halogen,

- 3) OR^4 ,
- 4) CF_3 ,
- 5) Unsubstituted or substituted aryl,
- 6) Unsubstituted or substituted $\text{C}_3\text{-C}_{10}$ cycloalkyl,
- 7) Unsubstituted or substituted heterocycle,
- 8) $\text{S(O)}_m\text{N(R}^4)_2$,
- 9) C(O)OR^4 ,
- 10) C(O)R^4 ,
- 11) CN ,
- 12) $\text{C(O)N(R}^4)_2$,
- 13) $\text{N(R}^4)\text{C(O)R}^4$,
- 14) NO_2 ; and
- 15) $\text{S(O)}_m\text{R}^6$;

m is independently 0, 1 or 2;

n is independently 0, 1, 2, 3, 4, 5 or 6;

s is 0 to 6;

t is 0, 1, or 2;


v is 0, 1 or 2;

w is 0, 1, 2, 3, or 4;

z is 1 or 2;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. (Original) The compound according to Claim 1, as illustrated by Formula II:



II

wherein:

----- represents an optional double bond;

X is C, N, S(O)_m or O;

G is H₂ or O;

R^a is independently selected from:

- 1) H,
- 2) C₁-C₆ alkyl,
- 3) Halogen,
- 4) Aryl,
- 5) Heterocycle,
- 6) C₃-C₁₀ cycloalkyl, and
- 7) OR⁴;

said alkyl, aryl, heterocycle and cycloalkyl is optionally substituted with at least one substituent selected from R⁷;

R¹ is independently selected from:

- 1) H,
- 2) (CR^{a2})_nR⁶,
- 3) (CR^{a2})_nC(O)R⁴,

- 4) $\text{C(O)N(R}^4\text{)}_2$,
- 5) $(\text{CR}^{\text{a}2})_n\text{OR}^4$,
- 6) $(\text{CR}^{\text{a}2})_n\text{N(R}^4\text{)}_2$,
- 7) $\text{S(O)}_m\text{R}^6$,
- 8) $\text{S(O)}_m\text{R}^6\text{OR}^4$,
- 9) $\text{C(O)N(R}^4\text{)(CR}^{\text{a}2})_n\text{R}^6$,
- 10) $\text{C(O)N(R}^4\text{)(CR}^{\text{a}2})_n\text{OR}^4$,
- 11) $\text{C(O)R}^6(\text{CR}^{\text{a}2})_n\text{R}^6$,
- 12) $\text{C(O)N(R}^4\text{)(CR}^{\text{a}2})_n\text{S(O)}_m(\text{CR}^{\text{a}2})_n\text{R}^6$,
- 13) $\text{C(O)N(R}^4\text{)(CR}^{\text{a}2})_n\text{C(O)R}^6$,
- 14) $\text{C(O)N(R}^4\text{)(CR}^{\text{a}2})_n\text{N(R}^4\text{)}_2$,
- 15) Halogen,
- 16) $\text{N(R}^4\text{)S(O)}_m\text{R}^6$,
- 17) $(\text{CR}^{\text{a}2})_n\text{C(O)OR}^4$, and
- 18) $\text{R}^6\text{C(O)OR}$;

R^2 is:

- 1) H,
- 2) Unsubstituted or substituted $\text{C}_1\text{-C}_{10}$ alkyl,
- 3) $\text{N(R}^4\text{)}_2$, or
- 4) OR^4 ;

R^4 is independently selected from:

- 1) H,
- 2) $\text{C}_1\text{-C}_6$ alkyl,
- 3) $\text{C}_3\text{-C}_{10}$ cycloalkyl,
- 4) Aryl,
- 5) Heterocycle,
- 6) CF_3 ,
- 7) $\text{C}_2\text{-C}_6$ alkenyl, and
- 8) $\text{C}_2\text{-C}_6$ alkynyl;

said alkyl, cycloalkyl, aryl, heterocycle, alkenyl and alkynyl is optionally substituted with at least one substituent selected from R⁷;

R⁵ is independently selected from:

- 1) H,
- 2) Halogen,
- 3) NO₂,
- 4) CN,
- 5) CR⁴=C(R⁴)₂,
- 6) C≡CR⁴,
- 7) (CR^{a2})_nOR⁴,
- 8) (CR^{a2})_nN(R⁴)₂,
- 9) C(O)R⁴,
- 10) C(O)OR⁴,
- 11) (CR^{a2})_nR⁴,
- 12) S(O)_mR⁶,
- 13) S(O)_mN(R⁴)₂,
- 14) OS(O)_mR⁶,
- 15) N(R⁴)C(O)R⁴,
- 16) N(R⁴)S(O)_mR⁶,
- 17) (CR^{a2})_nN(R⁴)R⁶,
- 18) (CR^{a2})_nN(R⁴)R⁶OR⁴,
- 19) (CR^{a2})_nN(R⁴)(CR^{a2})_nC(O)N(R⁴)₂,
- 20) N(R⁴)(CR^{a2})_nR⁶,
- 21) N(R⁴)(CR^{a2})_nN(R⁴)₂, and
- 22) (CR^{a2})_nC(O)N(R⁴)₂;

R⁶ is independently selected from:

- 1) C₁-C₆ alkyl,
- 2) Aryl,
- 3) Heterocycle, and
- 4) C₃-C₁₀ cycloalkyl;

said alkyl, aryl, heterocycle and cycloalkyl is optionally substituted with at least one substituent of R⁷;

R⁷ is independently selected from:

- 1) Unsubstituted or substituted C₁-C₆ alkyl,
- 2) Halogen,
- 3) OR⁴,
- 4) CF₃,
- 5) Unsubstituted or substituted aryl,
- 6) Unsubstituted or substituted C₃-C₁₀ cycloalkyl,
- 7) Unsubstituted or substituted heterocycle,
- 8) S(O)_mN(R⁴)₂,
- 9) C(O)OR⁴,
- 10) C(O)R⁴,
- 11) CN,
- 12) C(O)N(R⁴)₂,
- 13) N(R⁴)C(O)R⁴,
- 14) S(O)_mR⁶, and
- 15) NO₂;

m is independently 0,1 or 2;

n is independently 0, 1, 2, 3, 4, 5 or 6;

s is 0 to 6;

t is 0, 1, or 2;

v is 0, 1 or 2;

w is 0, 1, 2, 3, or 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.

3. (Original) The compound according to Claim 2 wherein:

R^a is independently selected from:

- 1) H,
- 2) C₁-C₆ alkyl,
- 3) Aryl, and
- 4) C₃-C₁₀ cycloalkyl;

said alkyl, aryl, and cycloalkyl is optionally substituted with at least one substituent selected from R⁷;

R¹ is independently selected from:

- 1) H,
- 2) (CR^{a2})_nR⁶,
- 3) (CR^{a2})_nC(O)R⁴,
- 4) C(O)N(R⁴)₂,
- 5) (CR^{a2})_nOR⁴,
- 6) (CR^{a2})_nN(R⁴)₂,
- 7) S(O)_mR⁶,
- 8) S(O)_mR⁶OR⁴,
- 9) C(O)N(R⁴)(CR^{a2})_nR⁶,
- 10) C(O)N(R⁴)(CR^{a2})_nOR⁴,
- 11) N(R⁴)S(O)_mR⁶,
- 12) (CR^{a2})_nC(O)OR⁴, and
- 13) R⁶C(O)OR;

R² is:

- 1) N(R⁴)₂, or
- 2) OR⁴;

s is 0 to 3;

or a pharmaceutically acceptable salt or stereoisomer thereof.

4. (Original) The compound according to Claim 3 wherein:

R¹ is independently selected from:

- 1) H,
- 2) (CR^{a2})_nR⁶,
- 3) (CR^{a2})_nC(O)R⁴,
- 4) C(O)N(R⁴)₂,
- 5) (CR^{a2})_nOR⁴,
- 6) (CR^{a2})_nN(R⁴)₂,
- 7) S(O)_mR⁶, and
- 8) S(O)_mR⁶OR⁴;

or a pharmaceutically acceptable salt or stereoisomer thereof.

5. (Original) A compound selected from:

5-Chloro-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
5-Bromo-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
5-Iodo-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
5-Methoxy-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
6-Methoxy-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
5-(Methylsulfonyl)-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
7-Amino-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
3-(Morpholin-4-ylsulfonyl)-5-nitro-1*H*-indole-2-carboxamide;
5-Chloro-3-(piperazin-1-ylsulfonyl)-1*H*-indole-2-carboxamide;
3-[(4-Benzylpiperazin-1-yl)sulfonyl]-5-chloro-1*H*-indole-2-carboxamide;
3-[(4-Acetylpiperazin-1-yl)sulfonyl]-5-chloro-1*H*-indole-2-carboxamide;
5-Chloro-3-(piperidin-1-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-Chloro-3-(pyrrolidin-1-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-Chloro-3-(thiomorpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

3-(Azetidin-1-ylsulfonyl)-5-chloro-1*H*-indole-2-carboxamide;

5-Chloro-3-[(oxidothiomorpholin-4-yl)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(1,1-dioxidothiomorpholin-4-yl)sulfonyl]-1*H*-indole-2-carboxamide;

cis-5-Chloro-3-(2,6-dimethylmorpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

trans-5-Chloro-3-(2,6-dimethylmorpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-Chloro-3-[(3-hydroxyazetidin-1-yl)sulfonyl]-1*H*-indole-2-carboxamide;

(±)-5-Chloro-3-{[2-(phenoxymethyl)morpholin-4-yl]sulfonyl}-1*H*-indole-2-carboxamide;

(*S*)-5-Chloro-3-{[2-(phenoxymethyl)morpholin-4-yl]sulfonyl}-1*H*-indole-2-carboxamide;

(*R*)-5-Chloro-3-{[2-(phenoxymethyl)morpholin-4-yl]sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-({4-[2-(dimethylamino)ethyl]-5-oxo-1,4-diazepan-1-yl}sulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-3-({5-oxo-1,4-diazepan-1-yl}sulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-3-[(3-oxopiperazin-1-yl)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[(3-hydroxyazetidin-1-yl)sulfonyl]-1*H*-indole-2-carboxamide;

(±)-5-Bromo-3-{[2-(aminocarbonyl)morpholin-4-yl]sulfonyl}-1*H*-indole-2-carboxamide;

3-(Azetidin-1-ylsulfonyl)-5-bromo-1*H*-indole-2-carboxamide;

5-Bromo-3-({4-[(4-methoxyphenyl)sulfonyl]piperazin-1-yl}sulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-3-({4-[(4-bromophenyl)sulfonyl]piperazin-1-yl}sulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-3-{[4-(3-morpholin-4-ylpropyl)-3-oxopiperazin-1-yl]sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-({4-[3-(dimethylamino)propyl]-3-oxopiperazin-1-yl}sulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-3-(2,5-dihydroxy-1*H*-pyrrol-1-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-3-(6-oxa-3-azabicyclo[3.1.0]hex-3-ylsulfonyl)-1*H*-indole-2-carboxamide;

(±)-5-Bromo-3-{[2-(phenoxymethyl)morpholino-4-yl]sulfonyl}-1*H*-indole-2-carboxamide;

(*S*)-5-Bromo-3-{[2-(phenoxymethyl)morpholino-4-yl]sulfonyl}-1*H*-indole-2-carboxamide;

(*R*)-5-Bromo-3-{[2-(phenoxymethyl)morpholino-4-yl]sulfonyl}-1*H*-indole-2-carboxamide;

6-Hydroxy-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

3-(Morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-(2-Furyl)-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

3-(Morpholin-4-ylsulfonyl)-5-(phenylethynyl)-1*H*-indole-2-carboxamide;

3-(Morpholin-4-ylsulfonyl)-5-(2-phenylethyl)-1*H*-indole-2-carboxamide;

5-Hex-1-ynyl-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-Hexyl-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

Methyl 2-(aminocarbonyl)-3-(morpholin-4-ylsulfonyl)-1*H*-indole-5-carboxylate;

3-(Morpholin-4-ylsulfonyl)-5-vinyl-1*H*-indole-2-carboxamide;

5-Hydroxy-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-Ethoxy-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
3-(Morpholin-4-ylsulfonyl)-5-propoxy-1*H*-indole-2-carboxamide;
5-Isopropoxy-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
5-Ethyl-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
2-(Aminocarbonyl)-3-(morpholin-4-ylsulfonyl)-1*H*-indol-5-yl methanesulfonate;
3-(Morpholin-4-ylsulfonyl)-5-prop-1-ynyl-1*H*-indole-2-carboxamide;
3-(Morpholin-4-ylsulfonyl)-5-thien-2-yl-1*H*-indole-2-carboxamide;
3-(Azetidin-1-ylsulfonyl)-5-methoxy-1*H*-indole-2-carboxamide;
5-Formyl-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
5-Methyl-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
7-(Acetylamino)-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
7-[(Methylsulfonyl)amino]-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
5-[[(4-Methoxyphenyl)amino]methyl]-3-morpholino-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
5-[[(2-Acetamide)amino]methyl]-3-morpholino-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
3-(Morpholino-4-ylsulfonyl)-5-phenyl-1*H*-indole-2-carboxamide;
3-(Morpholino-4-ylsulfonyl)-5-pyrazin-2-yl-1*H*-indole-2-carboxamide;
3-(Morpholino-4-ylsulfonyl)-5-pyridin-2-yl-1*H*-indole-2-carboxamide;
3-(Morpholino-4-ylsulfonyl)-5-pyridin-4-yl-1*H*-indole-2-carboxamide;
5-(1-Benzofuran-2-yl)-3-(morpholino-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
5-(5-Methyl-2-furyl)-3-(morpholino-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-(3,5-Dimethylisoxazole-4-yl)-3-(morpholino-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
3-(Morpholin-4-ylsulfonyl)-5-(1*H*-pyrrol-2-yl)-1*H*-indole-2-carboxamide;
3-(Morpholin-4-ylsulfonyl)-5-pyridin-3-yl-1*H*-indole-2-carboxamide;
3-(Morpholin-4-ylsulfonyl)-5-(1,3-thiazol-2-yl)-1*H*-indole-2-carboxamide;
3-(Morpholin-4-ylsulfonyl)-5-thien-3-yl-1*H*-indole-2-carboxamide;
5-(1-Benzothien-3-yl)-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
3-(Azetidin-1-yl)sulfonyl)-5-iodo-1*H*-indole-2-carboxamide;
3-[(3-Hydroxyazetidin-1-yl)sulfonyl]-5-iodo-1*H*-indole-2-carboxamide;
(±)-5-Iodo-3-{[2-(phenoxymethyl)morpholino-4-yl]sulfonyl}-1*H*-indole-2-carboxamide;
(*S*)-5-Iodo-3-{[2-(phenoxymethyl)morpholino-4-yl]sulfonyl}-1*H*-indole-2-carboxamide;
(*R*)-5-Iodo-3-{[2-(phenoxymethyl)morpholino-4-yl]sulfonyl}-1*H*-indole-2-carboxamide;
7-Amino-6-bromo-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
7-Amino-4,6-dibromo-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
6-Bromo-7-(dimethylamino)-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
3-(Morpholin-4-ylsulfonyl)-7-[(pyridin-4-ylmethyl)amino]-1*H*-indole-2-carboxamide;
7-[[2-Chloropyridin-4-yl)methyl]amino]-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
7-Nitro-3-{[(2*S*)-2-(phenoxymethyl)morpholin-4-yl]sulfonyl}-1*H*-indole-2-carboxamide;
7-Amino-3-{[(2*S*)-2-(phenoxymethyl)morpholin-4-yl]sulfonyl}-1*H*-indole-2-carboxamide;

3-[[*(2S)*-2-(Phenoxymethyl)morpholin-4-yl]sulfonyl]-7-[(pyridin-4-ylmethyl)amino]-1*H*-indole-2-carboxamide;

7-(Benzylamino)-3-[[*(2S)*-2-(phenoxymethyl)morpholin-4-yl]sulfonyl]-1*H*-indole-2-carboxamide;

7-Chloro-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

6-Bromo-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

7-Bromo-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

7-Cyano-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

(±)-7-(Methylsulfinyl)-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

7-Aminomethyl-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-Amino-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

(*S*)-5-Fluoro-3-[[2-(phenoxymethyl)morpholino-4-yl]sulfonyl]-1*H*-indole-2-carboxamide;

(*R*)-5-Fluoro-3-[[2-(phenoxymethyl)morpholin-4-yl]sulfonyl]-1*H*-indole-2-carboxamide;

5-Acetyl-amino-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-[(Methylsulfonyl)amino]-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

3-(Morpholin-4-ylsulfonyl)-5-[(trifluoroacetyl)amino]-1*H*-indole-2-carboxamide;

5-[(2-Aminoethyl)amino]-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-(Dimethylamino)-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

4,5-Dibromo-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5,6-Dibromo-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-4-nitro-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-6-nitro-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-6-amino-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-4-amino-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

(*S*)-3-{[2-(Phenoxymethyl)morpholino-4-yl]sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-({2-[(cyclohexylamino) carbonyl]morpholin-4-yl} sulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-3-({2-[(2,3-dihydro-1*H*-inden-1-ylamino)carbonyl] morpholin-4-yl} sulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-{[(2-phenylethyl)amino]carbonyl}morpholin-4-yl)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-{[(3-phenylpropyl)amino]carbonyl}morpholin-4-yl)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-{[(3,3-diphenylpropyl)amino]carbonyl}morpholin-4-yl)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-{[2-(3,4-dihydroisoquinolin-2(1*H*)-ylcarbonyl)morpholin-4-yl]sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-{[(2-phenoxyethyl)amino]carbonyl}morpholin-4-yl)sulfonyl]-1*H*-indole-2-carboxamide;

3-({2-[(3-Benzylpyrrolidin-1-yl)carbonyl]morpholin-4-yl} sulfonyl)-5-bromo-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-{[(1,2,3,4-tetrahydronaphthalen-2-ylmethyl)amino]carbonyl}morpholin-4-yl)sulfonyl]-1*H*-indole-2-carboxamide;

3-({2-[(Benzylamino)carbonyl]morpholin-4-yl}sulfonyl)-5-bromo-1H-indole-2-carboxamide;

5-Bromo-3-{[2-({[3-(trifluoromethyl)benzyl]amino}carbonyl)morpholin-4-yl}sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-({(2,2-diphenylethyl)amino}carbonyl)morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-({2-[(2,3-dihydro-1H-inden-2-ylamino)carbonyl]morpholin-4-yl}sulfonyl)-1H-indole-2-carboxamide;

7-{[2-(Aminocarbonyl)-5-bromo-1H-indol-3-yl}sulfonyl]-2-benzyl-7-aza-2-azoniaspiro[4.4]nonane;

5-Bromo-3-{[2-({[(5-methylpyrazin-2-yl)methyl]amino}carbonyl)morpholin-4-yl}sulfonyl]-1H-indole-2-carboxamide;

3-({[(4-{[2-(Aminocarbonyl)-5-bromo-1H-indol-3-yl}sulfonyl]morpholin-2-yl)carbonyl]amino}methyl)pyridine;

5-Bromo-3-[(2-({[(1-phenylethyl)amino]carbonyl)morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

1-(3-({[(4-{[2-(Aminocarbonyl)-5-bromo-1H-indol-3-yl}sulfonyl]morpholin-2-yl)carbonyl]amino}propyl)-1H-imidazole;

5-Bromo-3-{[2-({[(1R)-1-phenylethyl]amino}carbonyl)morpholin-4-yl}sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-({[(2-phenylpropyl)amino]carbonyl)morpholin-4-yl)sulfonyl]-1H-indole-

2-carboxamide;

3-[(2-{[Benzyl(methyl)amino]carbonyl}morpholin-4-yl)sulfonyl]-5-bromo-1H-indole-2-carboxamide;

1-[(4-{[2-(Aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}morpholin-2-yl)carbonyl]-4-benzylpiperazine;

2-([(4-{[2-(Aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}morpholin-2-yl)carbonyl]amino)methylpyridine;

5-Bromo-3-{[2-([2-(tert-butylthio)ethyl]amino)carbonyl]morpholin-4-yl)sulfonyl}-1H-indole-2-carboxamide;

3-([2-[(Benzhydrylamino)carbonyl]morpholin-4-yl)sulfonyl)-5-bromo-1H-indole-2-carboxamide;

5-Bromo-3-{[2-([(2S)-2-phenylcyclopropyl]amino)carbonyl]morpholin-4-yl)sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-([2-[(3-phenylpyrrolidin-1-yl)carbonyl]morpholin-4-yl)sulfonyl)-1H-indole-2-carboxamide;

5-Bromo-3-([2-[(4,4-diphenylpiperidin-1-yl)carbonyl]morpholin-4-yl)sulfonyl)-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{[(2,3-dihydro-1H-inden-2-ylmethyl)amino]carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-([2-[(2,3-dihydro-1H-inden-1-ylamino)carbonyl]morpholin-4-yl)sulfonyl)-1H-indole-2-carboxamide;

5-Bromo-3-({2-[(2,3-dihydro-1H-inden-1-ylamino)carbonyl]morpholin-4-yl}sulfonyl)-1H-indole-2-carboxamide;

5-Bromo-3-({2-[(3-pyridin-4-ylpyrrolidin-1-yl)carbonyl]morpholin-4-yl}sulfonyl)-1H-indole-2-carboxamide;

5-Bromo-3-[(2-[(2-hydroxy-2,3-dihydro-1H-inden-1-yl)amino]carbonyl)morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-({2-[(4-hydroxy-4-phenylpiperidin-1-yl)carbonyl]morpholin-4-yl}sulfonyl)-1H-indole-2-carboxamide;

3-{[2-(Anilinocarbonyl)morpholin-4-yl}sulfonyl}-5-bromo-1H-indole-2-carboxamide;

5-Bromo-3-[(2-[(2-oxo-2-phenylethyl)amino]carbonyl)morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-({2-[(neopentylamino)carbonyl]morpholin-4-yl}sulfonyl)-1H-indole-2-carboxamide;

5-Bromo-3-[(2-[(1,2-diphenylethyl)amino]carbonyl)morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-[(4-chlorophenyl)amino]carbonyl)morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-[(4-phenoxyphenyl)amino]carbonyl)morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-[(4-tert-butylphenyl)amino]carbonyl)morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-{[2-({[3-(2-oxopyrrolidin-1-yl)propyl]amino}carbonyl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-{[2-({[3-isopropoxypropyl]amino}carbonyl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-{[2-({[3-ethoxypropyl]amino}carbonyl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-{[2-({[2-cyclohex-1-en-1-ylethyl]amino}carbonyl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-{[2-({[2,2,3,3,4,4,4-heptafluorobutyl]amino}carbonyl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-{[2-({[3-isobutoxypropyl]amino}carbonyl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-{[2-({[3-butoxypropyl]amino}carbonyl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-{[2-({[2-thien-2-ylethyl]amino}carbonyl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;

2-({[4-({[2-(Aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl)morpholin-2-yl]carbonyl]amino}methyl)-1H-benzimidazole;

3-{[2-(Azepan-1-ylcarbonyl)morpholin-4-yl]sulfonyl}-5-bromo-1H-indole-2-carboxamide;

5-Bromo-3-({2-[(2-[(2,6-dichlorobenzyl)thio]ethyl)amino]carbonyl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;

3-{[2-([4-(Aminosulfonyl)benzyl]amino)carbonyl)morpholin-4-yl]sulfonyl}-5-bromo-1H-indole-2-carboxamide;

5-Bromo-3-{[2-(thiomorpholin-4-ylcarbonyl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-[2-{[(2-methoxyethyl)amino]carbonyl)morpholin-4-yl]sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[2-{[(2-methoxy-1-methylethyl)amino]carbonyl)morpholin-4-yl]sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[2-{[(1-ethylpropyl)amino]carbonyl)morpholin-4-yl]sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-{[2-([6-(dimethylamino)hexyl]amino)carbonyl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-[2-{[(tetrahydrofuran-2-ylmethyl)amino]carbonyl)morpholin-4-yl]sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[2-{[(1-phenylcyclopropyl)amino]carbonyl)morpholin-4-yl]sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-{[2-([phenyl(pyridin-4-yl)methyl]amino)carbonyl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-[2-{[(dicyclopropylmethyl)amino]carbonyl)morpholin-4-yl]sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[2-{[(1,4-dioxan-2-ylmethyl)amino]carbonyl)morpholin-4-yl]sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-{[2-({methyl[2-(4-methylphenoxy)ethyl]amino}carbonyl)morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-{[2-({[(1,1-dioxidotetrahydrothien-3-yl)methyl]amino}carbonyl)morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-{[2-({[2-(2-phenylethyl)pyrrolidin-1-yl]carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-{[2-({[(2-cyclohexylethyl)amino]carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

4-({[(4-{[2-(Aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}morpholin-2-yl)carbonyl]amino}methyl)-1-methyl-1H-imidazole;

5-Bromo-3-{[2-({[(1,1-dioxidotetrahydrothien-3-yl)amino]carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-{[2-({[(1-naphthylmethyl)amino]carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-{[2-({[(imidazo[2,1-b][1,3]thiazol-6-ylmethyl)amino]carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

3-{[2-({[2-(1,3-Benzothiazol-2-yl)pyrrolidin-1-yl]carbonyl}morpholin-4-yl)sulfonyl]-5-bromo-1H-indole-2-carboxamide;

5-Chloro-3-({2-[(2-ethoxyphenoxy)methyl]morpholin-4-yl)sulfonyl)-1H-indole-2-carboxamide;

5-Chloro-3-[(1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylsulfonyl]-1H-indole-2-carboxamide;

7-{[2-(Aminocarbonyl)-5-chloro-1H-indol-3-yl]sulfonyl}-3-benzyl-9-thia-7-aza-3-azoniabicyclo[3.3.1]nonane;

5-Chloro-3-{[2-(1H-indol-4-yl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Chloro-3-(2,3-dihydro-1,4-benzoxazepin-4(5H)-ylsulfonyl)-1H-indole-2-carboxamide;

3-[(Benzofuran-yl-1-oxa-8-azaspiro[4.5]dec-8-yl)sulfonyl]-5-chloro-1H-indole-2-carboxamide;

5-Chloro-3-{[4-fluoro-4-(3-phenylpropyl)piperidin-1-yl]sulfonyl}-1H-indole-2-carboxamide;

3-[(3-Benzyl-1-oxa-8-azaspiro[4.5]dec-8-yl)sulfonyl]-5-chloro-1H-indole-2-carboxamide;

3-({4-[(Benzyloxy)methyl]-4-phenylpiperidin-1-yl}sulfonyl)-5-chloro-1H-indole-2-carboxamide;

5-Chloro-3-{[4-hydroxy-4-(3-phenylpropyl)piperidin-1-yl]sulfonyl}-1H-indole-2-carboxamide;

7-{[2-(Aminocarbonyl)-5-chloro-1H-indol-3-yl]sulfonyl}-2-(4-chlorophenyl)-7-aza-2-azoniaspiro[4.4]nonane;

3-(1-{[2-(Aminocarbonyl)-5-chloro-1H-indol-3-yl]sulfonyl}piperidin-3-yl)-4-methyl-4H-1,2,4-triazole;

5-Chloro-3-{[3-(2-phenylethyl)piperidin-1-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Chloro-3-{[3-(2-phenylethyl)pyrrolidin-1-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Chloro-3-{[4-(cyclopropyl{[3-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-1-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Chloro-3-({2-[(4-chlorophenoxy)methyl]morpholin-4-yl}sulfonyl)-1H-indole-2-carboxamide;

Tert-butyl (1-{[2-(aminocarbonyl)-5-chloro-1H-indol-3-yl]sulfonyl}piperidin-3-yl)acetate;

3-[(3-Benzylpiperidin-1-yl)sulfonyl]-5-chloro-1H-indole-2-carboxamide;

5-Chloro-3-{[3-(2-methylphenyl)piperidin-1-yl]sulfonyl}-1H-indole-2-carboxamide;

2-(1-{[2-(Aminocarbonyl)-5-chloro-1H-indol-3-yl]sulfonyl}piperidin-4-yl)-N,N-dimethylethanamine;

1-(1-{[2-(Aminocarbonyl)-5-chloro-1H-indol-3-yl]sulfonyl}piperidin-4-yl)-3-(ethoxycarbonyl)piperidine;

5-Bromo-3-{[3-(4-tert-butoxybenzyl)piperidin-1-yl]sulfonyl}-1H-indole-2-carboxamide;


5-Bromo-3-{[4-(3-phenylpropyl)piperidin-1-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-N-methoxy-N-methyl-3-{[2-(phenoxyethyl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;


or a pharmaceutically acceptable salt or stereoisomer thereof.

6. (Original) The compound according Claim 5 that is selected from


3-(Morpholin-4-ylsulfonyl)-5-(1,3-thiazol-2-yl)-1H-indole-2-carboxamide




(*S*)-5-Iodo-3-([2-(phenoxymethyl)morpholino-4-yl]sulfonyl)-1*H*-indole-2-carboxamide




5-Bromo-6-amino-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide




5-bromo-3-({2-[(2,3-dihydro-1*H*-inden-2-ylamino)carbonyl]morpholin-4-yl}sulfonyl)-1*H*-indole-2-carboxamide



5-bromo-3-([2-([2-(tert-butylthio)ethyl]amino)carbonyl]morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide



5-bromo-3-([2-([1-(1-naphthylmethyl)amino]carbonyl]morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide



or a pharmaceutically acceptable salt or stereoisomer thereof.

7. (Original) A pharmaceutical composition which is comprised of a compound in accordance with Claim 1 and a pharmaceutically acceptable carrier.

8. (Original) A method of modulating the catalytic activity of protein kinases in a mammal in need thereof comprising contacting the protein kinase with a compound of Claim 1.

9. (Original) The method of Claim 7 wherein the protein kinase is an RTK.

10. (Original) The method of Claim 8, wherein the RTK is selected from IR, IGF-1R and IRR.

11. (Original) A method of treating or preventing a PK-related disorder in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

12. (Original) A method of Claim 11, wherein the PK-related disorder is an IGF-1R-related disorder selected from:

- 1) cancer,
- 2) diabetes,
- 3) an autoimmune disorder,
- 4) a hyperproliferation disorder,
- 5) aging,
- 6) acromegaly, and
- 7) Crohn's disease.

13. (Original) A method of treating cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

14. (Original) A method of treating retinal vascularization comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

15. (Original) A method of treating cancer which comprises administering a

therapeutically effective amount of a compound of Claim 1 in combination with a second compound selected from:

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor, and
- 10) an angiogenesis inhibitor.

16. (Original) The method of Claim 15, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.

17. (Original) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy.

18. (Original) The method of Claim 15 wherein radiation therapy is also administered.

19. (Original) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and paclitaxel or trastuzumab.

20. (Original) A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and a GPIIb/IIIa antagonist.

21. (Canceled)

22. (Canceled)